Transitioning From Cyclosporine to Alefacept in Psoriasis

Completed · Phase 2

Conditions studied: Psoriasis

In brief

The purpose of this study is to devise a safe and effective method for transitioning patients from cyclosporine to alefacept.

Key facts

Study ID

NCT00143806

Run by

University of Medicine and Dentistry of New Jersey

People needed

13

Starts

2003-10-01

Expected to finish

2007-05-01

Last updated by the study team

2009-01-05

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult psoriasis patients (18 to 80 years old), who are well controlled on cyclosporine (Static PGA score of mild, minimal or clear) and who need or desire to stop cyclosporine and start alefacept.

You may not qualify if…

• CD4 <400
• Active infection (other than trivial URI, etc.)
• History of AIDS or Hepatitis B, C
• Inability to understand consent or comply with study requirements
• Pregnancy or Lactation
• History of heart or liver disease

Where it is running

• UMDNJ Clinical Research Center — New Brunswick, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.